GSK PLC - London-based pharmaceutical and biotechnology - Tests of Arexvy, GSK’s vaccine against respiratory syncytial virus, shows it can protect a wider range of adults. The vaccine already is approved for use in adults aged 60 years and above in more than 50 countries and in adults 50 to 59 in the US and some European countries. New phase IIb and IIIb trials on adults aged 18 to 49 years at risk of RSV show that two doses of Arexvy bring an immune response for adults aged 18 and above that is similar to one dose in adults aged 50 or more, with an acceptable safety profile.
RSV is a contagious virus that can cause severe respiratory illness and affects about 64 million people of all ages globally every year, GSK says. ‘These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at risk from RSV disease,’ says Chief Scientific Officer Tony Wood. ‘They also provide valuable insights into the potential impact of a second dose for certain populations.’
Current stock price: 1,458.50 pence, up 0.7% in London on Thursday morning
12-month change: down 0.8%
Copyright 2024 Alliance News Ltd. All Rights Reserved.
